Company / SG&A per Share
Spyre Therapeutics, Inc. SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.80
FY2025
5-year range
$0.44 / $15.28
FY2021-FY2025
Trend
-37.4%
vs FY2024
Sector context
#136 of 210
Health Care
What the data says
At $0.80, Spyre Therapeutics, Inc.'s sg&a per share ranks #75 of 210 in the Health Care sector. SG&A per Share has fluctuated over the past 10 years, ranging from $0.42 in FY2019 to $15.28 in FY2023.
Based on SEC 10-K filings.
0.80 in FY2025 with a 5-year CAGR of +12.9%.
Improved from $15.28 to $0.80 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +21.6%
- 5-Year CAGR
- +12.9%
- 10-Year CAGR
- -
Sector benchmark
#75 of 210 in Health CareTop 35% of 210This company $0.80 Sector average $40.75
▼
-98.0% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share decreased 37.4% year-over-year.
- Ranks #136 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2023.
- Lowest sg&a per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.80 | -37.4% |
| FY2024 | $1.27 | -91.7% |
| FY2023 | $15.28 | +3352.9% |
| FY2022 | $0.44 | -22.3% |
| FY2021 | $0.57 | +31.2% |
| FY2020 | $0.43 | +4.2% |
| FY2019 | $0.42 | -17.2% |
| FY2018 | $0.50 | -24.4% |
| FY2017 | $0.67 | -22.4% |
| FY2016 | $0.86 | -91.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026